Hot Keywords
metabolic syndrome kidney atherosclerosis endocrine disorder NAFLD diabetes MAFLD adipose tissue obesity obesity metabolism fatty liver steatosis fibrosis cardiovascular insulin resistance hypertension metabolomics precision medicine hypertriglyceridemia

Top
Topic: Metabolism and Cancer

A special issue of Metabolism and Target Organ Damage

ISSN 2769-6375 (Online)

Submission deadline: 30 May 2023

Guest Editor(s)

  • Rouba Ali-Fehmi, MD

    Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI, USA.

    Website | E-mail

  • Giampiero Francica, MD

    Chief Diagnostic and Interventional Ultrasound Unit, Pineta Grande Hospital, Castel Volturno, Italy.

    Website | E-mail

  • Mira Kheil, MD

    Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI, USA.

    Website | E-mail

  • Luca Roncucci, MD, PhD
    Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

    Website | E-mail

Special Issue Introduction

Over the last three decades, the global prevalence of type 2 diabetes (T2D) and obesity - that often cluster with arterial hypertension and dyslipidemia which, collectively, are often alluded to as the “metabolic syndrome” (MetS) - have increased two- and sixfold, respectively. Globally, this upward spiraling epidemic is projected to exact a major toll in terms of lives lost and financial burden for years to come.

Tissue damage associated with the above metabolic disease drivers was initially thought to result solely from the degenerative changes in the vasculature and the abnormal fatty changes occurring in the liver (often alluded to as “nonalcoholic fatty liver disease, i.e. NAFLD or MAFLD, i.e. metabolic-associated fatty liver disease they cause) and other viscera, eventually resulting in progressively irreversible organ loss of function in a proportion of cases.

However, more recently, MetS and its individual features together with their closely and bi-directionally associated fatty liver syndromes (NAFLD/MAFLD), have also been shown to associate with incidence and aggressivity of multiple cancer types.

This novel epidemiological and pathogenic paradigm highlights the crucial role that altered cell metabolic homeostasis may have in cancer development and progression. This intriguing area of research places itself them at the crossroad of multiple medical specialties spanning from epidemiology and molecular biology to internal medicine, oncology, metabolism, endocrinology, and imaging techniques. With this backset, Metabolism and Target Organ Damage has now established to launch a special issue focusing on the role of obesity, T2D and additional features of the MetS in cancer. Our interest is principally devoted, but not limited, to colo-rectum, liver, uterus and ovary.

Collectively, these specific cancer types had an incidence of 26% and a mortality of 24% on a world-wide basis in 2020. These impressive epidemiological data fully support the focus on this issue being placed on delving deeper into the complex and multifactorial nature of these malignancies, specifically shedding light in the role that metabolic disturbances play in it.

As the Guest Editors of this Special Issue, we are confident that the papers we present, contributed by experts from all over the world, will provide invaluable insights and point out future lines of investigation into this multidisciplinary topic.


Participants

1. Rouba Ali-Fehmi, Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI, USA.
2. Enrica Baldelli, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
3. Giampiero Francica, Chief Diagnostic and Interventional Ultrasound Unit, Pineta Grande Hospital, Castel Volturno, Italy.
4. Mohamed Ali Garada, Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI, USA.
5. Mira Kheil, Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI, USA.
6. Lauren Larson, Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI, USA.
7. Amedeo Lonardo, Department of Internal Medicine, Ospedale Civile di Baggiovara, Modena, Italy.
8. Fulvio Lonardo, Department of Pathology, School of Medicine, Wayne State University, Detroit, Michigan, USA.
9. Simonetta Lugari, Division of Internal Medicine and Metabolism, Department of Internal Medicine, University Hospital of Modena, Modena, Italy.
10. Maurizio Pompili, Internal Medicine and Gastroenterology, Hepatology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
11. Luca Roncucci, Department of Diagnostic and Clinical Medicine, and Public Health, University of Modena and Reggio Emilia, Modena, Italy.
12. Noor Suleiman, School of Medicine, Wayne State University, Detroit, MI, USA
13. Lara Zraik, Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI, USA.

Submission Deadline

30 May 2023

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://mtodjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=mtod&SpecialIssueId=mtod220530
Submission Deadline: 30 May 2023
Contacts: Doreen Deng, Managing Editor, editorialoffice@mtodjournal.net
                  Zoe Zhang, Assistant Editor, zoe@mtodjournal.net

Published Articles

This special issue is now open for submission.
© 2016-2022 OAE Publishing Inc., except certain content provided by third parties